Atrophic Vaginitis — Patent Landscape
3
Approved drugs
146
Active US patents
56/100
Avg vulnerability
—
Annual revenue covered
Originators in Atrophic Vaginitis
Cliff calendar — next 15 years
12
28
3
29
10
30
31
31
76
32
2
33
2
34
4
36
2
37
1
38
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Estrace
ESTRADIOL
|
Pfizer | 101 | 37 | — | 2028-07-10 |
|
Slynd
DROSPIRENONE
|
Exeltis Usa Inc | 42 | 64 | — | 2028-01-15 |
|
Endometrin
progesterone
|
Ferring | 3 | 66 | — | 2029-02-03 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 11951213 | Slynd | method of use | 81 | 2031-06-28 |
| 11951213 | Slynd | method of use | 81 | 2031-06-28 |
| 12090231 | Slynd | method of use | 81 | 2031-06-28 |
| 12090231 | Slynd | method of use | 81 | 2031-06-28 |
| 11617751 | Slynd | method of use | 76 | 2030-07-17 |
| 11617751 | Slynd | method of use | 76 | 2030-07-17 |
| 11413249 | Slynd | method of use | 76 | 2031-06-28 |
| 10603281 | Slynd | method of use | 76 | 2031-06-28 |
| 9603860 | Slynd | method of use | 76 | 2031-06-28 |
| 10179140 | Slynd | method of use | 76 | 2031-06-28 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 11795178 | Estrace | composition of matter | 0 | 2033-09-27 |
| 12325714 | Estrace | composition of matter | 0 | 2033-09-27 |
| 11865179 | Estrace | composition of matter | 0 | 2032-11-21 |
| 11865179 | Estrace | composition of matter | 0 | 2032-11-21 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 7300935 | Estrace | composition of matter | 0 | 2029-01-28 |
Related
- Atrophic Vaginitis — full disease profile
- AI Patent Landscape Report — type "atrophic vaginitis" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner